Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) has outlined the scientific rationale supporting its lead drug candidate Xanamem® (emestedastat) as a potential treatment for Alzheimer’s disease, with results from the company’s first pivotal clinical trial expected in November 2026.
The company presented an overview of Xanamem and its development program in a 12-minute podium presentation titled Advancing Oral Xanamem in Alzheimer’s Disease at the annual Bioshares Biotech Summit in Queenstown, New Zealand.
Glencore PLC (LSE:GLEN) reported an 86% jump in first-half earnings and announced an additional $1.5 billion of shareholder returns as it enjoyed a boost from higher commodity prices and volatile energy markets.
Underlying profit (adjusted EBITDA) rose to $10.11 billion from $5.43 billion a year earlier, on revenue that increased 49% to $174.4 billion.
Right Resources Ltd (ASX:RRE) has produced a high-grade tungsten sink product from preliminary metallurgical testwork at its Blue prospect near Tumbarumba in New South Wales, supporting further evaluation of a gravity-led processing route.
Heavy Liquid Separation testing on a 32-kilogram composite sample returned a product grading 66.5% tungsten trioxide at a crush size below 1 millimetre, with an indicative tungsten recovery of 81.6%.
BlinkLab Ltd (ASX:BB1, OTC:BKLBF, FRA:P41) has reported positive results from a European ADHD study, marking a major step toward expanding its smartphone-based diagnostic platform beyond autism.
The study achieved sensitivity of 82% and specificity of 83% in children aged six to 17, supporting further development of BlinkLab Dx2, an artificial intelligence model designed to identify digital neurobehavioural markers associated with attention-deficit/hyperactivity disorder.
Artificial intelligence is emerging as a two-sided challenge for Australia’s electricity system, simultaneously giving cyber attackers more powerful tools and driving a rapid expansion of energy-hungry data centres.
The Australian Energy Market Operator (AEMO) has warned that advances in generative AI are lowering the technical barriers to sophisticated cyberattacks against power stations, electricity networks and other operational infrastructure.
Barys Resources Ltd (ASX:BRY)has commenced a detailed exploration program across its newly acquired, 100%-owned tenements in Kazakhstan, targeting gold and potential copper mineralisation ahead of an initial drilling campaign.
The five-week program will cover seven priority alteration zones identified across the company’s 335-square-kilometre licence package in the North Balkhash region.
Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) (Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF)) remains on track to begin a Phase II trial of HMBD-002 in the fourth quarter of 2026, according to Edison Investment Research, which has maintained its A$84.4 million valuation, equivalent to 5.5 cents per share.
Edison said preparations for the study continued to advance during the June quarter, with good manufacturing practice drug substance production completed and final drug product expected to be released in September.
Mastermyne Group Ltd (ASX:MYE, FRA:024) has secured a new mining services contract at the Dendrobium underground metallurgical coal mine in New South Wales, potentially generating about A$255 million in gross revenue over six years.
The contract with GM3 has an initial two-year term, expected to deliver around A$85 million in revenue, together with two optional two-year extensions.